Crypto Crash Ahead? (27 Experts Weigh In)

27 of the world's brightest minds in crypto are gathering to reveal their top picks and predictions for the massive crypto surge expected in Q4. This could very well be the best wealth-building opportunity of our lifetimes…

Nicholas Haft Biography and Net Worth

Director of Finch Therapeutics Group

Nicholas Haft is Managing Director of OMX Ventures. Nicholas also serves as the Chief Executive Officer of Delix Therapeutics. He previously served as managing director of Arcos Ventures. He currently serves on the boards of directors of multiple private companies in the life sciences industry.

Nicholas has a BS from the Wharton School of the University of Pennsylvania.

How do I contact Nicholas Haft?: The corporate mailing address for Mr. Haft and other Finch Therapeutics Group executives is , , . Finch Therapeutics Group can also be reached via phone at 617-229-6499 and via email at [email protected]. Learn More on Nicholas Haft's contact information.
Has Nicholas Haft been buying or selling shares of Finch Therapeutics Group?: Nicholas Haft has not been actively trading shares of Finch Therapeutics Group during the last ninety days. Most recently, on Monday, December 20th, Nicholas Haft bought 2,128 shares of Finch Therapeutics Group stock. The stock was acquired at an average cost of $305.40 per share, with a total value of $649,891.20. Learn More on Nicholas Haft's trading history.
Who are Finch Therapeutics Group's active insiders?: Finch Therapeutics Group's insider roster includes Nicholas Haft (Director), and Jeffery Smisek (Director). Learn More on Finch Therapeutics Group's active insiders.
Are insiders buying or selling shares of Finch Therapeutics Group?: During the last twelve months, insiders at the sold shares 2 times. They sold a total of 8,112 shares worth more than $22,420.74. The most recent insider tranaction occured on March, 28th when Director Jeffery A. Smisek sold 6,642 shares worth more than $17,069.94. Insiders at Finch Therapeutics Group own 44.9% of the company. Learn More about insider trades at Finch Therapeutics Group.
Information on this page was last updated on 3/28/2024.

Nicholas Haft Insider Trading History at Finch Therapeutics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2021	Buy	2,128	$305.40	$649,891.20

Nicholas Haft Buying and Selling Activity at Finch Therapeutics Group

Finch Therapeutics Group Company Overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $11.95

$11.95

$12.10

50 Day Range

MA: $11.93

$11.00

$13.69

2 Week Range

Now: $11.95

$0.80

$14.26

Volume

1,026 shs

Average Volume

5,408 shs

Market Capitalization

$19.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34